GlobalData on Tuesday said that the universal COVID-19 vaccine could be a game-changer, especially in highly populated developing countries like India. According to the company, since the beginning of the coronavirus pandemic, multiple new variants with enhanced transmissibility and increased virulence have emerged, causing repeated surges in case numbers and hospitalisations.
Recently, the Coalition for Epidemic Preparedness Innovations (CEPI) partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine. According to reports, CEPI is backing the consortium with $19.3 million to establish pre-clinical and clinical proof of concept.
“Since the beginning of the pandemic in 2020, 44.6 million individuals have been affected by COVID-19 in India, and about half a million have died as a result. GlobalData’s ‘Pharmaceutical Intelligence Center’ states that India has the second highest number of confirmed cases of COVID-19 worldwide, after the US. Though there are some FDA-approved antiviral treatments, including monoclonal antibodies, which can effectively reduce the chances of being hospitalised/ mortality from the disease, the consensus is that vaccination is the best method for controlling the rising cases,” GlobalData said on Tuesday.
Moreover, the COVID-19 market in India is mainly dominated by vaccines rather than therapeutics. Globally, there are 40 marketed COVID-19 vaccines, nine of which are marketed in India (Corbevax, Covaxin, Covishield, Covovax, Gemcovac, Incovacc, Sputnik Light, Sputnik-V, ZyCov-D). Among these, Serum Institute of India’s (SII) Covishield and Bharat Biotech’s Covaxin have gained widespread use.
“For most of the existing vaccines for SARS-CoV-2, the duration of protection against the virus is unclear. Hence, there is a need for multiple boosters. Many vaccines have shown varied and limited efficacies against the different variants of SARS-CoV-2. India has spent about $2.3 billion (INR 196.75 billion) until December 2020 to procure different COVID-19 vaccines. In addition, the government has allotted $4.09 billion (INR 350 billion) in 2021-2022 union budget for COVID-19 vaccination, a number which will continue to grow with the need for additional boosters in the future. Thus, investing in a universal COVID-19 vaccine could prove better for public health as well as more cost-effective for the government in the long-term,” Dr. Pavan Sunkireddy, Pharma Analyst at GlobalData, said on Tuesday.
According to GlobalData, scientists are investigating various vaccine technologies to develop a universal vaccine for SARS-CoV-2. However, the challenge of developing a universal vaccine is complex as the areas of the virus targeted by the COVID-19 vaccines developed in early stages have since mutated in subsequent variants, a phenomenon known as “vaccine escape.”
The data and analytics company maintained that a universal vaccine must target common areas of the virus that are less likely to be impacted by these types of mutations. To date, no variant-proof vaccines in development have yet progressed beyond Phase I clinical trials (for example, Gritstone Bio’s mRNA vaccine CORAL), but the results of the studies thus far seem promising, it claimed.
“COVID-19 variants continue to cause multiple deadly outbreaks. Though most of the eligible Indian population is vaccinated, given that the available vaccines are not equally effective against all variants, another outbreak can occur. As a result, in developing countries like India, universal vaccine could be a great asset not only in reducing the cost of vaccination in the long-term but also in offering a wide range of protection,” Dr. Sunkireddy said on Tuesday.
ALSO READ | China’s focus to develop domestic medical device industry may discourage MNCs: GlobalData
